Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN3048 and REGN3051 in Healthy Adults
NCT03301090Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REGN3048 and REGN3051 in Middle East respiratory syndrome (MERS), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2018; status: completed.
02
Drugs
REGN3048REGN3051
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT03301090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301090.